
Radiation protection — Performance criteria for laboratories performing initial cytogenetic dose assessment of mass casualties in radiological or nuclear emergencies — General principles and application to dicentric assay

Radioprotection — Critères de performance pour les laboratoires pratiquant l'estimation dosimétrique préliminaire par cytogénétique en cas d'accident radiologique ou nucléaire affectant un grand nombre de personnes — Principes généraux et application au test dicentrique



This document is a preview generated by ELS



COPYRIGHT PROTECTED DOCUMENT

© ISO 2022

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Page

Foreword.....	iv
Introduction.....	v
1 Scope.....	1
2 Normative references.....	1
3 Terms and definitions.....	1
4 Responsibility of the laboratory.....	3
4.1 Awareness of this document.....	3
4.2 Biological dosimetry request and confidentiality.....	3
4.3 Pre-planning.....	4
4.4 Responsibility during service.....	4
5 Biological dosimetry process in radiological or nuclear mass-casualty incidents.....	5
6 Emergency response of the lead laboratory.....	5
7 Design of a laboratory network.....	5
7.1 Overview.....	5
7.2 Preparedness of the laboratory network.....	6
7.3 Laboratory network operation.....	6
7.3.1 General.....	6
7.3.2 Lead laboratory responsibilities.....	7
7.3.3 Associate laboratory responsibilities.....	7
8 Expected results.....	8
8.1 General.....	8
8.2 Whole-body exposure.....	8
8.3 Inhomogeneous exposure.....	9
9 Quality assurance and quality control.....	9
9.1 Overview.....	9
9.2 Quality control.....	10
9.2.1 General.....	10
9.2.2 Quality control procedures.....	10
9.2.3 Performance checks of sample transport integrity.....	10
9.2.4 Performance checks of sample integrity by the laboratory.....	10
9.2.5 Performance checks of instrumentation.....	10
9.2.6 Performance checks of sample protocol.....	11
9.2.7 Performance checks of exposure categorization.....	11
9.2.8 Performance checks of sample scoring.....	11
9.2.9 Performance checks of dose and confidence intervals estimation.....	11
9.2.10 Performance checks of the generation of reports results.....	11
9.2.11 Performance checks of a data security plan.....	11
9.2.12 Performance of the network.....	12
Annex A (informative) Interactions between requestors and biological dosimetry laboratories.....	13
Annex B (informative) Guidance for threshold of detection when the dicentric assay is analysed using manual scoring procedures.....	15
Annex C (informative) Example group sample report.....	16
Bibliography.....	18

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 85, *Nuclear energy*, Subcommittee SC 2, *Radiological protection*.

This second edition cancels and replaces the first edition (ISO 21243:2008), which has been technically revised.

The main changes are as follows:

- Annex D (Estimates of dose and 95 % confidence limits for selected observations of numbers of dicentric and cells) has been removed;
- in [8.1](#), General: the number of cells to be scored has been moved to [Annex B](#);
- in [8.2](#), Whole body exposure: addition of a description of when not to assume an acute exposure by looking at the variance/mean and a phrase stating that for low LET radiation doses below ~0.3Gy, linearity can be assumed (as with high LET).

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

The potential for nuclear and radiological emergencies involving mass casualties from accidental or malicious acts recommends generic procedures for initial dose assessment to help the development of medical response capabilities. A mass-casualty incident is defined here as an event that exceeds the local medical resources. Biological dosimetry, based on cytogenetic analysis using the dicentric assay, typically applied for accidental dose assessment, has been defined in ISO 19238. Initial assessment refers to an expedited version of the dicentric assay that evaluates chromosome damage in a small number of cells and would be used in an emergency situation where rapid analysis is needed. This results in an estimated dose with high uncertainty but allows for exposure categorization. This document focuses on the use of the dicentric assay for initial cytogenetic analysis in the case of mass-casualty incidents. Many of the concepts discussed here can be applied to other biological dosimetry methods. The initial dose evaluation/categorization performed according to this document can be complemented by a more detailed analysis to reduce uncertainties according to ISO 19238 recommendations.

After a large-scale radiation emergency or malevolent act involving radioactive materials, physicians are primarily concerned with preserving life and evaluating medical signs and symptoms for early treatment decisions. It is expected that patients have already been assessed clinically and triaged on the basis of any prodromal signs and symptoms of overexposure plus available information concerning their involvement in the incident. In this early-response phase of a radiological or nuclear emergency, the purpose of cytogenetic assessment is to quickly estimate the absorbed radiation dose for each referred patient to supplement such early clinical assessment.

The role of this cytogenetic assessment is to confirm whether displayed symptoms can be attributed to radiation exposure or due to an unrelated cause. It is expected that the cytogenetic report be sufficiently informative to provide guidance to medical staff as they proceed with clinical management of the patients. This management can potentially include expedited identification of: (1) concerned, but not radiation-exposed public, through provision of advice and reassurance; (2) low/moderately irradiated patients, who do not need out-patient observation or clinical intervention; and (3) highly irradiated patients requiring active treatment for potentially life-threatening injury through optimized use of limited medical resources.

Several clinical triage systems have been developed in which irradiated patients are allocated to dose ranges (or acute-radiation-sickness response categories) based on the severity of prodromal symptoms that correspond with mild to very severe injuries. Enough experience in using clinical triage schemes (e.g. from Chernobyl) has been gained to show that the early sorting of persons into these dose or response category cohorts was adequate for the emergency planning of the patients' management. However, as time progresses clinicians are looking for more accurate estimations of doses both in the low-dose range, where irradiated persons require counselling on risks of late stochastic effects, and also for higher doses, for anticipating the shorter-term sequelae of severe tissue reactions.

It should be noted that the initial clinical triage interprets the symptoms in terms of the early phase response to partial or whole-body exposure. Protracted and fractionated exposures need higher doses in order to produce the same severity of responses.

It is expected that the cytogenetic methods achieve an initial estimate of dose or response category that is quantitatively more precise than the clinically derived categories, and take into account any evidence that the exposure might not have been received acutely or to the whole body. It is expected that the need for precision be set against the competing requirement for expedited results and it is necessary that this judgement be made at the time of the event. This will depend on the anticipated number of patients, the surge capacity of the laboratory and the rate at which the blood samples are received by the laboratory.

Expert cytogenetic biological dosimetry laboratories typically function to support national radiation protection programmes and emergency response schemes. Several of these national cytogenetic biological dosimetry laboratories have independently and successfully performed initial dose assessment in actual and simulated mass-casualty incidents. Their approaches included pre-planning, reagent stockpiling, simplified sample processing, automation, as well as modifying some of the ISO 19238 scoring criteria. Several of these national cytogenetic biological dosimetry laboratories

have established networks of supplementary, satellite cytogenetic laboratories, both nationally as well as internationally. Building upon their experience, this document is intended to define criteria for performing quality-assured initial assessment of radiation dose using cytogenetic methods.

The primary purpose of this document is to provide a guideline to all biological dosimetry laboratories for performing the dicentric assay for initial dose assessment using documented and validated procedures. Secondly, it can facilitate the involvement of cytogenetic biological dosimetry networks to increase analysis capacity while ensuring dose estimates provided by the network laboratories are valid. Finally, it is expected that laboratories that are newly commissioned to carry out the initial cytogenetic analysis conform to this document in order to ensure reproducible and accurate dose assessments.

This document is written outlining the procedures for the dicentric assay specific to initial biological dosimetry assessments for potential overexposures involving mass radiological/nuclear casualties. These procedures can also be applied to other biological dosimetry methods such as the cytokinesis blocked micronucleus (CBMN) assay as described in ISO 17099. If appropriate, semi-/automation procedures can be included in the process as long as they have been well validated and described by the laboratory applying them. The criteria for selecting the level of scoring usually depends on the application of the results (e.g. medical management, radiation-protection management, record keeping and medical/legal requirements). For example, selected cases can have more cells analysed to produce a more accurate evaluation of high partial-body exposure; secondly, doses can be estimated for persons exposed to doses below the threshold for acute tissue reactions, by using the ISO 19238 criteria. These latter data also assist in counselling for the risk of late stochastic disease.

Part of the information presented in this document can be found in other international guidelines and scientific publications, primarily in ISO 19238 and the 2011 of International Atomic Energy Agency's EPR-Biodosimetry publication^[1]. However, this document details and standardizes the quality assurance and quality control of performance criteria for cytogenetic assessment of individual exposures in radiological or nuclear mass casualty events. This document is generally compliant with ISO/IEC 17025^[2], with particular consideration given to the specific needs of initial biodosimetry. The expression of uncertainties in dose estimations given in this document conforms with the ISO Guide 98^[3] and ISO 5725 (all parts)^[4].

Radiation protection — Performance criteria for laboratories performing initial cytogenetic dose assessment of mass casualties in radiological or nuclear emergencies — General principles and application to dicentric assay

1 Scope

The purpose of this document is to give an overview of the minimum requirements for performing the dicentric assay with quality control measures using mitogen stimulated peripheral blood lymphocytes for initial assessment of individuals involved in a mass casualty scenario. The dicentric assay is the use of chromosome damage to quickly estimate approximate radiation doses received by individuals in order to supplement the early clinical categorization of casualties.

This document focuses on the organizational and operational aspects of applying the dicentric assay in an initial assessment mode. The technical aspects of the dicentric assay can be found in ISO 19238.

This document is applicable either to an experienced biological dosimetry laboratory working alone or to a network of collaborating laboratories (as defined in [Clause 7](#)).

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements for this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 19238, *Radiological protection — Performance criteria for service laboratories performing biological dosimetry by cytogenetics*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 19238 and the following apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

3.1

absorbed dose

D

differential quotient of $\bar{\epsilon}$ with respect to m , where $\bar{\epsilon}$ is the mean energy imparted by ionizing radiation to matter of mass m :

$$D = \frac{d\bar{\epsilon}}{dm}$$

Note 1 to entry: The gray is a special name for joule per kilogram and is to be used as the coherent SI unit for absorbed dose.

[SOURCE: ISO/IEC 80000-10, 10.81.1]